- Overview
- Data/Specifications
- Literature/Support
- How To Use
- Related Products
Overview
Monoclonal antibody to delta-unsaturated glucuronic acid adjacent to N-acetylgalactosamine- 4-sulphate in the non-reducing terminal dissacharide “stub” of 4-sulphated chondroitin sulfate that is produced after chondroitinase digestion of chondroitin-4- sulphate glycosaminoglycan chains (chondroitinase ABC or ACII) or dermatan sulphate glycosaminoglycan chains (chondroitinase ABC or chondroitinase B).
Related Terms/Symbols:
- Chondroitin-4-sulfate
- C-4-S
- Dermatan-sulfate
Data/Specifications
Immunogen: Bovine nasal cartilage aggrecan that had been deglycosylated with chondroitinase ABCdigestion; i.e. BNC (ABC) Core (see Couchman et al 1984 and Caterson et al 1985).
Clone: 2B6
Isotype: IgG
Host: Mouse
Purity: Affinity purified
Specificity: Chondroitin-4-sulphate (C-4-S) after treatment with Chondroitinase ABC or ACII. Dermatansulphate (DS) neoepitope after treatment with Chondroitinase ABC or B.
Form: liquid
Storage: -20° C
Literature/Support
Antibody to Chondroitinase-generated C-4-S and DS neoepitope Insert (PDF, 338 KB)
Joint Disease and Aggrecan (blog post)
Caterson, B, Christner, JE, Baker, JR, Couchman, JR. (1985) Production and character- ization of monoclonal antibodies directed against connective tissue proteoglycans Fed Proc 44,386-393
Couchman, J.R., Caterson, B., Christner, J.E. and Baker, J.R. (1984). Mapping by Monoclonal Antibody Detection of Glycosaminoglycans in Connective Tissues. Nature 307: 650-652
Rees SG, Flannery CR, Little CB, Hughes CE, Caterson B & Dent CM (2000). Catabolism of aggrecan, decorin and biglycan in tendon. Biochem J. 350: 181-188.
Hayes AJ, Hall A, Brown L, Tubo R & Caterson B (2007). Macromolecular organization and in vitro growth characteristics of scaffold-free neocartilage grafts. J Histochem Cytochem. 55(8):853-66.
Hayes AJ, Hughes CE & Caterson B (2008). Antibodies and immunohistochemisrty in extracellular matrix research. Methods 45: 10-21
Stefan Milz, Frank Regner, Reinhard Putz, and Michael Benjamin. Expression of a Wide Range of Extracellular Matrix Molecules in the Tendon and Trochlea of the Human Superior Oblique MuscleInvestigative Ophthalmology and Visual Science. 2002;43:1330-1334
Hedlund, H, Hedbom, E, Heinegard, D, Mengarelli-Widholm, S, Reinholt, FP, Svensson, O. (1999) Association of the aggrecan keratan sulfate-rich region with collagen in bovine articular cartilage J Biol Chem 274,5777-5781
How To Use
Applications
- ELISA
- Western Blot
- Immunohistochemistry
Technical Notes
Pretreatment with Chondroitinase required. 1x10-3 U per 10 mg GAG at 37 °C for 1 hour.
Related Products
ebiomall.com
>
>
>
>
>
>
>
>
>
>
>
>
1、RNA干扰基因蛋白的表达的过程是瞬间的还是一步步的,需要一段时间才能使目的基因沉默。
2、关于siRNA的合成,有好多种,但文献报道的一般是化学合成的和通过构建质粒表达载体完成的,但据俺了解,体外转录和RNA酶III酶切从时间上和价格上都比这两种方法好,为何这么多研究者青睐这两种方法呢
3、俺打算用此方法研究某个基因的功能,想先进行体外实验,然后再进行在体实验,请教各位,用哪种方法比较好?
4、如果用质粒的话,究竟用哪种质粒好呢?听说质粒比较昂贵,看到好多文献所用质粒都是惠赠的,怎么才能通过惠赠的方式获得质粒载体呢
或许俺提的这些问题过于低级,恳切希望各位高手予以解答,不才万分感激!
详见:http://zhidao.baidu.com/question/1831844001436785260.html?fr=iks&word=%B2%A1%B6%BE%B5%C4%B8%B4%D6%C6%D6%DC%C6%DA%B5%C4%B9%FD%B3%CC%3F&ie=gbk
1.如果在引物的5’引物引入了T7启动子,3‘引物也引入了polyT,PCR扩增出全长片段,回收纯化之后可以用来直接做体外转录么?为什么看到文献里都是先把这个PCR片段连接到载体里面,扩增之后提取出来线性化之后,再进行体外转录。是不是转录对模板的量有要求?
2.如果使用一些带有T7启动子序列的载体比如pBluescriptSK,在启动子序列和酶切位点之间还有多余的一段序列,这段序列也会被启动子转录,这一小段多余的序列是否会对接下来的转染以及病毒拯救带来影响?
3.有人在做反向遗传么,哪些载体可以用来进行体外转录?插入片段为7.5K。
量水用精细般瓶装乙醚即
现在小弟碰见一个难题,我想克隆一个基因,但是我在NCBI一检索,发现别人只发表了这个基因的DNA全长,但是,CDNA没有发表,也没有发表文章,想请问下,在不知道CDNA的情况下,请问我应该如何做这个基因的克隆???(全基因组也不知道,其他生物没有这种基因)
我非医学专业人士,但因工作需要了解这家公司和它的产品品质,希望用过或对比过的童鞋能帮我科普下专业知识,万分感谢~~具体问题可以私聊哈,如果能留下QQ、电话最佳~~~
暂无品牌问答